核苷（酸）类似物治疗乙型肝炎的长期安全性和疗效。
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B.
机构信息
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
出版信息
Liver Int. 2018 Feb;38 Suppl 1:84-89. doi: 10.1111/liv.13641.
Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.
长期使用核苷（酸）类似物治疗慢性乙型肝炎（CHB）通常是必需的，以实现持久的病毒抑制。因此，当前的指南推荐使用具有最佳耐药谱的最有效药物。恩替卡韦（ETV）、富马酸替诺福韦二吡呋酯（TDF）和替诺福韦艾拉酚胺（TAF）是 CHB 的一线单药治疗药物。所有这些药物在抑制病毒复制方面都非常有效，但安全性略有不同。这篇综述提供了自 ETV 和 TDF 最初被批准用于治疗慢性乙型肝炎以来的 10 年中获得的长期疗效和安全性数据的概述，以及近期 TAF 在 CHB 患者中的数据。
Zotero 插件